Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation ( rTMS ) in Peripheral Neuropathic Pain: A GRADE ‐Assessed Meta‐Analysis of Randomized Sham‐Controlled Trials
Authors:
- Omar Khaled AbdelsalamOAOmar Khaled Abdelsalam
- Rashad G. MohamedRMRashad G. Mohamed
- Mostafa Adel T. MahmoudMMMostafa Adel T. Mahmoud
- Ali I. Abbas DawoudADAli I. Abbas Dawoud
- Rehab Salama Saleh LabibRLRehab Salama Saleh Labib
- Belal Mohamed HamedBHBelal Mohamed Hamed
- Maickel AbdelMesehMAMaickel AbdelMeseh
- Sohieb HedawySHSohieb Hedawy
- Moaz Elsayed AbouelmagdMAMoaz Elsayed Abouelmagd
- Abdallah AbbasAAAbdallah Abbas
- Ahmed M. RaslanARAhmed M. Raslan
- 22 May 2026
- journal article
- research article
- Published by Wiley in Pain Practice
- Vol. 26 (5) , e70169
Abstract
Background: Peripheral neuropathic pain (PNP) results from damage to peripheral nerves, leading to intractable or exaggerated pain. Repetitive transcranial magnetic stimulation (rTMS) is a non‐invasive therapeutic method that modulates cortical neuronal activity and can promote endogenous opioid release, with a potential analgesic effect. This meta‐analysis evaluates the efficacy and safety of rTMS use in PNP patients. Methods: We systematically searched PubMed, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) evaluating rTMS in PNP. The primary outcome was pain intensity. Statistical analysis was performed using Review Manager version 5.4.1. Risk of bias was assessed using the Cochrane RoB 2 tool, and a random‐effects model was used to compute pooled estimates, expressed as standardized mean differences (SMD), mean differences (MD), and risk ratios (RR) with 95% confidence intervals (CI). Results: Nine studies with 435 patients were included. rTMS significantly improved pain intensity (SMD = −1.11, 95% CI: [−1.72, −0.49]; p = 0.0004) and achieved a 30% reduction in pain (RR = 3.31, 95% CI: [0.98, 11.20]; p = 0.05). Improvements in sleep quality (SMD = −1.02, p = 0.26) and Patient Global Impression of Change were not statistically significant (RR = 1.70, p = 0.13). Safety analysis showed no significant increase in adverse events such as headache (RR = 1.32, p = 0.1), dizziness, pain at the stimulation site, sleep disturbances, or cognitive complaints. Conclusion: rTMS significantly reduces pain in PNP patients without major safety concerns. While findings support its clinical utility, high heterogeneity and limited long‐term data suggest further standardized trials are warranted. Prospero Registration: CRD42024628350Keywords
This publication has 30 references indexed in Scilit:
- H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain and Symptoms of Anxiety and Depression in Patients With Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover StudyNeuromodulation: Technology at the Neural Interface, 2024
- Posterior-superior insular deep transcranial magnetic stimulation alleviates peripheral neuropathic pain — A pilot double-blind, randomized cross-over studyNeurophysiologie Clinique, 2021
- Chemotherapy‐induced peripheral neuropathy: A current reviewAnnals of Neurology, 2017
- The Efficacy of Daily Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Burning Mouth Syndrome (BMS): A Randomized Controlled Single-blind StudyBrain Stimulation, 2016
- From pulses to pain relief: an update on the mechanisms of rTMS‐induced analgesic effectsEuropean journal of pain, 2015
- Neuropharmacological basis of rTMS-induced analgesia: The role of endogenous opioidsPain, 2011
- rTMS for Suppressing Neuropathic Pain: A Meta-AnalysisThe Journal of Pain, 2009
- Prevalence of chronic pain with neuropathic characteristics in the general populationPain, 2008
- Reduction of intractable deafferentation pain by navigation-guided repetitive transcranial magnetic stimulation of the primary motor cortexPain, 2006
- Afferent pain pathways: a neuroanatomical reviewBrain Research, 2004